Cardiovascular protection for all individuals at high risk: Evidence-based best practice

Clinical Research in Cardiology

Volumn 97, Issue 10, 2008, Pages 713-725

  Bakris, George ^a   Böhm, Michael ^b   Dagenais, Gilles ^c   Diener, Hans Christoph ^d   Fujita, Toshiro ^e   Gorelick, Philip ^f   Kjeldsen, Sverre Erik ^g   Laakso, Markku ^h   Mancia, Giuseppe ⁱ   Pitt, Bertram ^j   Sharma, Arya ^k   Sleight, Peter ^l   Teo, Koon ^m   Unger, Thomas ⁿ   Weber, Michael ^o   Williams, Bryan ^p   Zannad, Faiez ^q  

^a UNIVERSITY OF CHICAGO   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF TOKYO   (Japan)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF EASTERN FINLAND   (Finland)

ⁱ SAN GERARDO HOSPITAL   (Italy)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF ALBERTA   (Canada)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m MCMASTER UNIVERSITY   (Canada)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o STATE UNIVERSITY OF NEW YORK   (United States)

^p LEICESTER ROYAL INFIRMARY   (United Kingdom)

^q UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

Cardiovascular risk management; Evidence based medicine; High cardiovascular risk

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EPROSARTAN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; SIMVASTATIN; TELMISARTAN;

ARTERY DISEASE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; COUGHING; CREATININE BLOOD LEVEL; DISEASE CONTROL; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GENETIC MARKER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MICROANGIOPATHY; MONOTHERAPY; MYALGIA; MYOPATHY; PRIMARY PREVENTION; PROGNOSIS; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; THROMBOCYTE AGGREGATION; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VULNERABLE POPULATION;

BENCHMARKING; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 52649099445     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-008-0713-2     Document Type: Review

References (87)

1. ADVANCE Collaborative Group 2007 Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 829 840
2. American Diabetes Association 2004 Aspirin therapy in diabetes Dia Care 26 S87 S88
3. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 71 86
4. L Backlund J Bring L-E Strender 2004 How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Prim Health Care Res Dev 5 145 152
5. Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, Franklin B, Sanderson B, Southard D, American Heart Association Exercise, Cardiac Rehabilitation, Prevention Committee, the Council on Clinical Cardiology, American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American Association of Cardiovascular and Pulmonary Rehabilitation (2007) Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on cardiovascular nursing, epidemiology and prevention, and nutrition, physical activity, and metabolism; and the American Association of cardiovascular and pulmonary rehabilitation. Circulation 115:2675-2682
6. CM Ballantyne 1998 Low-density lipoproteins and risk for coronary artery disease Am J Cardiol 82 3Q 12Q
7. V Barrios C Escobar A Calderon R Echarri V González-Pedel LM Ruilope CONTROLRISK Investigators 2007 Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK Study J Hum Hypertens 21 479 485
8. P Barter AM Gotto JC LaRosa J Maroni M Szarek SM Grundy JJ Kastelein V Bittner JC Fruchart Treating to New Targets Investigators 2007 HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 1301 1310
9. DL Bhatt KA Fox W Hacke PB Berger HR Black WE Boden P Cacoub EA Cohen MA Creager JD Easton MD Flather SM Haffner CW Hamm GJ Hankey SC Johnston KH Mak JL Mas G Montalescot TA Pearson PG Steg SR Steinhubl MA Weber J Booth EJ Topol CHARISMA Investigators 2005 A global view of atherothrombosis: baseline characteristics in the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial Am Heart J 150 401e1 401e7
10. DL Bhatt KA Fox W Hacke PB Berger HR Black WE Boden P Cacoub EA Cohen MA Creager JD Easton MD Flather SM Haffner CW Hamm GJ Hankey SC Johnston KH Mak JL Mas G Montalescot TA Pearson PG Steg SR Steinhubl MA Weber DM Brennan L Fabry-Ribaudo J Booth EJ Topol CHARISMA Investigators 2006 Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 1706 1717
11. Blood Pressure Lowering Treatment Trialists' Collaboration 2003 Effects of blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 1527 1535
12. P Brindle A Beswick T Fahey S Ebrahim 2006 Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review Heart 92 1752 1759
13. CAPRIE Steering Committee 1996 A randomised, blinded trial of clodipogrel versus aspirin in patients at risk of ischemic events (CAPRIE) Lancet 348 1329 1339
14. NC Campbell J Thain HG Deans LD Ritchie JM Rawles JL Squair 1998 Secondary prevention in coronary heart disease: baseline survey of provision in general practice BMJ 316 1430 1434
15. MP Carey SA Maisto SC Kalichman AD Forsyth EM Wright BT Johnson 1997 Enhancing motivation to reduce the risk of HIV infection for economically disadvantaged urban women J Consult Clin Psychol 65 531 541
16. Cholesterol Treatment Trialists' (CTT) Collaboration 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278
17. AJ Claxton J Cramer C Pierce 2001 A systematic review of the association between dose regimens and medication compliance Clin Ther 23 1296 1310
18. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone MJ Thomason MI Mackness V Charlton-Menys JH Fuller CARDS Investigators 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative Atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 685 696
19. R Collins J Armitage S Parish P Sleight R Peto Heart Protection Study Collaborative Group 2003 MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2005 2016
20. J Critchley S Capewell 2004 Smoking cessation for the secondary prevention of coronary heart disease Cochrane Database Syst Rev 1 CD003041
21. C Cuspidi E Ambrosioni G Mancia AC Pessina B Trimarco A Zanchetti APROS Investigators 2002 Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the assessment of prognostic risk observational survey. J Hypertens 20 1307 1314
22. GR Dagenais J Pogue K Fox ML Simoons S Yusuf 2006 Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 368 581 588
23. EL De Schryver A Algra J van Gijn 2007 Dipyridamole for preventing stroke and other vascular events in patients with vascular disease Cochrane Database Syst Rev 18 3 CD001820
24. RB Devereux K Watchell E Gerdts K Boman MS Nieminen V Papademetriou J Rokkedal K Harris P Aurup B Dahlöf 2004 Prognostic significance of left ventricular mass change during treatment of hypertension JAMA 292 2350 2356
25. A Di Castelnuovo S Rotondo L Iacoviello MB Donati G De Gaetano 2002 Meta-analysis of wine and beer consumption in relation to vascular risk Circulation 105 2836 2844
26. Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 393 403
27. HC Diener Bogousslavsky LM Brass C Cimminiello L Csiba M Kaste D Leys J Matias-Guiu HJ Rupprecht MATCH Investigators 2004 Aspirin and clopidogrel compared to clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo controlled trial. Lancet 64 331 337
28. HC Diener L Cunha C Forbes J Sivenius P Smets A Lowenthal 1996 European stroke prevention study 2: dipyridamole and acetylsalicylic acid in secondary prevention of stroke J Neurol Sci 143 1 13
29. HC Diener R Sacco S Yusuf 2007 Rationale, design and baseline data of a randomized, double blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the prevention regimen for effectively avoiding second strokes trial (PRoFESS) Cerebrovasc Dis 23 368 380
30. PJ Elmer E Obarzanek WM Vollmer D Simons-Morton VJ Stevens DR Young PH Lin C Champagne DW Harsha LP Svetkey J Ard PJ Brantley MA Proschan TP Erlinger LJ Appel PREMIER Collaborative Research Group 2006 Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial Ann Intern Med 144 485 495
31. L Erhardt 2005 Managing cardiovascular risk: reality Vs. perception Eur Heart J 7 Suppl. L L11 L15
32. ESPRIT The Esprit Study Group 2006 Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial Lancet 376 1665 1673
33. EUROASPIRE II Study Group 2001 Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme Eur Heart J 22 554 572
34. Finchham JE (1996) Advancing prescription medicine compliance: new paradigms, new practices. J Pharmcoepidemiol 3:37-48
35. JD Fisher WA Fisher 1992 Changing AIDS-risk behavior Psychol Bull 111 455 474
36. JD Fisher WA Fisher SJ Misovich DL Kimble TE Malloy 1996 Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population Health Psychol 15 114 123
37. R Garg S Yusuf 1995 Overview of randomized trials of angiotensin- converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ace inhibitor trials JAMA 273 1450 1456
38. L Hansson A Zanchetti SG Carruthers B Dahlöf D Elmfeldt S Julius J Ménard KH Rahn H Wedel S Westerling 1998 Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial Lancet 351 1755 1762
39. G Harmon J Lefante M Krousel-Wood 2006 Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications Curr Opin Cardiol 21 310 315
40. RG Hart O Benavente R McBride LA Pearce 1999 Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 492 501
41. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators 2000 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO_HOPE substudy Lancet 335 253 259
42. Heart Outcomes Prevention Evaluation Study Investigators 2000 Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 145 153
43. Heart Protection Study Collaborative Group 2002 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 7 22
44. FDR Hobbs L Erhardt 2002 Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey Fam Pract 19 596 604
45. MC Houston 2002 The role of vascular biology, nutrition and nutraceuticals in the prevention and treatment of hypertension J Am Nutraceut Assoc 1 5 70
46. H Ibsen ME Olsen K Watchtell K Borch-Johnsen LH Lindholm CE Mogensen B Dahlöf RB Devereux U de Faire F Fyhrquist S Julius SE Kjeldsen O Lederballe-Pedersen MS Nieminen P Omvik S Oparil Y Wan 2005 Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study Hypertension 45 198 202
47. JJ Kastelein SI van Leuven L Burgess GW Evans JA Kuivenhoven PJ Barter JH Revkin DE Grobbee WA Riley CL Shear WT Duggan ML Bots RADIANCE 1 Investigators 2007 Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 1620 1630
48. I Kawachi GA Golditz MJ Stampfer WC Willett JE Manson B Rosner FE Speizer CH Hennekens 1994 Smoking cessation and time course of decreased risk of coronary heart disease in middle-aged women Arch Intern Med 145 169 175
49. SE Kjeldsen RE Kolloch G Leonetti JM Mallion A Zanchetti D Elmfeldt I Warnold L Hansson 2000 Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension optimal treatment J Hypertens 18 629 642
50. R Kunz C Friedrich M Wolbers JF Mann 2008 Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease Ann Intern Med 148 30 48
51. H Leventhal L Cameron 1987 Behavioral theories and the problem of compliance Patient Educ Couns 10 117 138
52. Look AHEAD Research Group 2007 Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial Diab Care 30 1374 1383
53. G Mancia G De Backer A Dominiczak R Cifkova R Fagard G Germano G Grassi AM Heagerty SE Kjeldsen S Laurent K Narkiewicz L Ruilope A Rynkiewicz RE Schmieder HA Boudier A Zanchetti A Vahanian J Camm R De Caterina V Dean K Dickstein G Filippatos C Funck-Brentano I Hellemans SD Kristensen K McGregor U Sechtem S Silber M Tendera P Widimsky JL Zamorano S Erdine W Kiowski E Agabiti-Rosei E Ambrosioni LH Lindholm M Viigimaa S Adamopoulos E Agabiti-Rosei E Ambrosioni V Bertomeu D Clement S Erdine C Farsang D Gaita G Lip JM Mallion AJ Manolis PM Nilsson E O'Brien P Ponikowski J Redon F Ruschitzka J Tamargo P van Zwieten B Waeber B Williams Management of Arterial Hypertension of the European Society of Hypertension, European Society of Cardiology 2007 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC) J Hypertens 25 1105 1187
54. G Mancia R Volpe S Boros M Ilardi C Giannattasio 2004 Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care J Hypertens 22 51 57
55. DB Matchar DC McCrory LA Orlando MR Patel UD Patel MB Patwardhan B Powers GP Samsa RN Gray 2008 Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension Ann Intern Med 148 16 29
56. SA Mazzuca 1982 Does patient education in chronic disease have therapeutic value? J Chron Dis 35 521 529
57. Medications and older people. FDA consumer magazine, September-October 1997 issue; (Pub no. FDA 03-1315C). Revised 2003
58. CD Morris S Carson 2003 Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 139 56 70
59. National Council on Patient Information, Education (August 2007) Enhancing prescription medicine adherence: a national action plan. NCPIE
60. SE Nissen JC Tardif SJ Nicholls JH Revkin CL Shear WT Duggan W Ruzyllo WB Bachinsky GP Lasala EM Tuzcu ILLUSTRATE Investigators 2007 Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 1304 1316
61. MH Olsen K Watchtell JN Bella V Palmieri E Gerdts G Smith MS Nieminen B Dahlöf H Ibsen RB Devereux 2004 Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy J Hum Hypertens 8 453 459
62. ONTARGET Investigators S Yusuf KK Teo J Pogue L Dyal I Copland H Schumacher G Dagenais P Sleight C Anderson 2008 Telmisartan, ramipril, or both in patients at high risk of vascular events N Engl J Med 358 1547 1559
63. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497
64. P Pais J Pogue H Gerstein E Zachariah D Savitha S Jayprakash PR Nayak S Yusuf 1996 Risk factors for acute myocardial infarction in Indians: a case-control study Lancet 348 358 363
65. Prescription drug compliance a significant challenge for many patients (29 March 2005) Harris interactive. http://www.harrisinteractive.com
66. JO Prochaska 1992 Strong and weak principles for progressing from precontemplation to action Health Psychol 13 47 51
67. JO Prochaska CC DiClemente JC Norcross 1992 In search of how people change. Applications to addictive behaviors Am Psychol 47 1102 1114
68. PROGRESS Collaborative Group 2001 Randomised trial of a perindopril based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 1033 1041
69. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S, American Heart Association Council for High Blood Pressure Research, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 115:2761-2788
70. Sabate E (2003) Adherence to long-term therapies: evidence for action. World Health Organization http://www.who.int/chp/knowledge/publications/ adherence_full_report.pdf
71. RE Schmieder J Schrader W Zidek U Tebbe WD Paar P Bramlage D Pittrow M Böhm 2007 Low-grade albuminuria and cardiovascular risk. What is the evidence? Clin Res Cardiol 96 247 257
72. J Schrader S Luders A Kulschewski F Hammersen K Plate J Berger W Zidek P Dominiak HC Diener MOSES Study Group 2005 Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) Stroke 36 1218 1226
73. V Snow MD Aronson ER Hornbake C Mottur-Pilson KB Weiss Clinical Efficacy Assessment Subcommittee of the American College of Physicians 2004 Lipid control in the management of type 2 diabetes mellitus Ann Intern Med 140 644 649
74. ML Stefanick S Mackey M Sheehan N Ellsworth WL Haskell PD Wood 1998 Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol N Engl J Med 339 12 20
75. PA Tabor DA Lopez 2004 Comply with us: improving medication adherence J Pharm Pract 17 167 181
76. M Tanasescu MF Leitzmann EB Rimm FB Hu 2003 Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes Circulation 107 2435 2439
77. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, ONTARGET/TRANSCEND Investigators (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ongoing Telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. Am Heart J 148:52-61
78. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators 2006 High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 549 559
79. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators 2007 Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 217 227
80. J Tuomilehto J Lindström JG Erikkson TT Valle H Hämä läinen P Ilanne-Parikka S Keinänen-Kiukaanniemi M Laakso A Louheranta M Rastas V Salminen M Uusitupa Finnish Diabetes Prevention Study Group 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance N Engl J Med 344 1343 1350
81. T Unger M Stoppelhaar 2007 Rationale for double renin-angiotensin- aldosterone system blockade Am J Cardiol 100 3A 25J 31J
82. BG Vickrey TS Rector SL Wickstrom PM Guzy EM Sloss PB Gorelick S Garber DF McCaffrey MD Dake RA Levin 2002 Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease Stroke 33 901 906
83. J Vivancos-Mora AC Gil-Nunez 2005 Lipids and stroke: the opportunity of lipid-lowering treatment Cerebrovasc Dis 20 Suppl 2 53 67
84. C Weimar M Goertler J Rother EB Ringelstein H Darius DG Nabavi IH Kim K Theobald HC Diener 2007 Systemic risk score evaluation in ischemic stroke patients (SCALA): a prospective cross sectional study in 85 German stroke units J Neurol 254 1562 1568
85. S Yusuf S Hawken S Ounpuu T Dans A Avezum F Lanas M McQueen A Budaj P Pais J Varigos L Lisheng INTERHEART Study Investigators 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 937 952
86. S Yusuf S Reddy S Ôunpuu S Anand 2001 Global burden of cardiovascular diseases, part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies Circulation 104 2855 2864
87. A Zanchetti L Hansson B Dahlöf S Julius J Ménard I Warnold H Wedel HOT Study Group 2002 Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk J Hypertens 20 2301 2307